Baxter International's Management Presents at Citi 2013 Global Healthcare Conference (Transcript)

Baxter International Inc (NYSE:BAX) February 25, 2013 3:00 PM ET

Executives

Robert J. Hombach - Chief Financial Officer and Corporate Vice President
Mary Kay Ladone - Vice President of Investor Relations

Analysts

Matthew J. Dodds - Citigroup Inc, Research Division

Matthew J. Dodds - Citigroup Inc, Research Division

I'm Matthew Dodds of Citigroup, for those on the webcast. And I'm very pleased next to have Baxter International. We've got Bob Hombach, who's the Chief Financial Officer; and Mary Kay Ladone, who's Vice President of Investor Relations, with us. Baxter, we've got a lot to talk about. We've got a lot going on in the recombinant side, a lot going on in the immune globulin side, we've got Gambro.

So Bob is going to give a short presentation, and then we're going to do mostly Q&A. And I'm going to encourage everyone to chime in during the Q&A. So with that, Bob, thank you.

Robert J. Hombach

Thanks, Matt. And good afternoon, everyone. Before I begin my formal comments, I'll just remind you of our Safe Harbor statement. For more information, please refer to our website for our SEC filings, including our 10-K and 10-Q filings.

As you know, Baxter is a global, diversified healthcare leader with extensive global footprint. We remain committed to advancing new therapies, to improving the safety and cost-effectiveness of treatment and expanding access to care around world. Baxter has built up a very strong international presence over the last 80 years. Today, approximately 60% of our sales are outside the U.S. We continue to see great growth opportunities going forward particularly in emerging markets. Today for Baxter, emerging markets represents approximately 20% of our total sales. Over the next 5 years, given the strong growth prospects we see, we expect emerging markets to account for approximately 30% of our sales by the end of 2017.